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Abstract 
Oral squamous cell carcinoma (OSCC) is the eleventh most common cancer in the 
world. The five-year survival rate of patients who are diagnosed with OSCC at an early 
stage is about 80-90%. On the other hand, at an advanced stage, the five-year survival 
rate is less than 30%. Therefore, it is important to detect OSCC at an early stage. In this 
study, we subjected OSCC patients’ serum samples to gas chromatography/mass 
spectrometry (GC/MS)-based metabolomic analysis. The serum samples of 18 OSCC 
patients were used as a training set. Their preoperative serum metabolite levels were 
compared with those of healthy volunteers. In addition, the pre- and postoperative 
serum metabolite levels of these patients were also compared. The serum samples 
collected from another 17 OSCC patients and healthy volunteers were used as a 
validation set. In addition, 12 patients with oral diseases other than OSCC were also 
used to evaluate the reliability of the extracted serum metabolite biomarker candidates. 
The metabolites that displayed significant differences were subjected to multiple logistic 
regression analysis, and it was found that models based on candidate biomarker pairs 
possessed greater accuracy than single biomarker candidates. GC/MS-based 
metabolomic analysis is a promising method for detecting early-stage OSCC.   
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Oral squamous cell carcinoma; Oral cancer; Biomarker; Gas chromatography/mass 
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Introduction 
Oral squamous cell carcinoma (OSCC) is the eleventh most common cancer in the 
world. In 2008, there were about 263,000 new oral cancer cases and about 127,000 
deaths from the disease [1]. The five-year survival rate of patients that are diagnosed 
with OSCC at an early stage is about 80-90%. On the other hand, when OSCC is 
diagnosed at an advanced stage the five-year survival rate is less than 30%. Overall, 
only about 50% of OSCC patients survive for five years. The treatment of OSCC at an 
advanced stage can have adverse effects on the patient’s appearance and can also lead to 
a variety of problems with eating and speaking. In addition, advanced-stage OSCC 
causes a greater reduction in quality of life than other cancers. Thus, it is important to 
detect OSCC at an early stage; however, this is currently difficult. The standard initial 
diagnostic approaches to OSCC are mainly dependent on inspection and manipulation. 
Conventional tumor markers, e.g., SCC antigen, and diagnostic imaging, such as 
computed tomography and biopsy, are not suitable for OSCC screening because 
conventional tumor markers have low sensitivity for the disease, diagnostic imaging is 
expensive, and biopsy is invasive. Therefore, new methods for detecting OSCC at an 
early stage are required. 
 
The metabolome, which is the comprehensive characterization of the small molecular 
weight metabolite profiles, is beginning to gain attention. Analyzing metabolite profiles 
allows genotype-phenotype relationships to be evaluated because the metabolome is 
closely related to physiological functions and pathological characteristics. In 
metabolomics, nuclear magnetic resonance (NMR) spectroscopy, gas 
chromatography/mass spectrometry (GC/MS), liquid chromatography/mass 
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spectrometry (LC/MS), and capillary electrophoresis/mass spectrometry (CE/MS) have 
been used to measure the levels of a variety of metabolites. In this study, we used 
GC/MS-based metabolomic analysis to discover new biomarkers and screening methods 
for OSCC. The main advantages of GC/MS are its simplicity of use, the abundance of 
databases for serum metabolite analysis, and its high repeatability; therefore, GC/MS is 
suitable for screening studies aimed at discovering metabolite biomarkers of OSCC. We 
have performed several metabolomic studies using GC/MS [2] and reported serum 
metabolite biomarkers for various cancers [3,4,5,6,7]. In this study, we used 18 OSCC 
patients and 18 healthy volunteers as a training set, and an OSCC prediction model was 
established via multiple logistic regression analysis. Then, the validity of the prediction 
model was assessed using a validation set consisting of OSCC patients (N=17) and 
healthy volunteers (N=17). 
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Materials and methods 
Participants 
This study was approved by the ethics committee at Kobe University Graduate School 
of Medicine. The human samples were used in accordance with the guidelines of Kobe 
University Hospital, and written informed consent was obtained from all subjects. For 
the training set, serum samples were collected from 18 patients who underwent 
resection for OSCC. Serum samples were collected from these patients both before 
surgery and over 2 weeks after the operation. In addition, serum samples were also 
obtained from healthy volunteers in the morning after overnight fasting. For the 
validation set, serum samples were collected prior to surgery from 17 patients who were 
scheduled to undergo resection for OSCC as well as from 17 healthy volunteers. Serum 
samples were also obtained prior to surgery from 12 patients who underwent operations 
for oral diseases other than oral cancer, and further samples were collected from 10 of 
these patients over 2 weeks after the operation. The serum samples from the OSCC and 
oral disease patients were collected at Kobe University Hospital between April 2011 
and March 2012. The patients were diagnosed by microscopy, biopsy, or surgical 
resection and classified using the TNM classification of the Union for International 
Cancer Control (UICC). The serum samples from the healthy volunteers were obtained 
at another facility. The characteristics of all subjects are summarized in Table 1. The 
serum was separated by centrifugation at 3,000 x g for 10 min at 4
o
C, before being 
transferred to a clean tube and stored at -80
o
C until use. 
 
Experimental procedures 
The extraction of low molecular weight metabolites was performed according to the 
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method described in our previous report [8], and 0.5 mg/ml of 2-isopropylmalic acid 
(Sigma-Aldrich, Tokyo, Japan) dissolved in distilled water was used as an internal 
standard. Then, oximation and the subsequent derivatization for GC/MS measurement 
were carried out according to a previously described method [8]. 
 
 GC/MS analysis was performed using a GCMS-QP2010 Ultra spectrometer (Shimadzu 
Co., Kyoto, Japan) with a fused silica capillary column (CP-SIL 8 CB low bleed/MS; 
inner diameter, 30 mm × 0.25 mm; film thickness, 0.25 m; Agilent Co., Palo Alto, 
CA), according to a previously described method [9]. The front inlet temperature was 
230
o
C, and the flow rate of helium gas through the column was 39.0 cm/sec. The 
column temperature was held at 80
o
C for 2 min and then raised by 15
o
C/min to 330
o
C 
and held there for 6 min. The transfer line and ion-source temperatures were 250
o
C and 
200
o
C, respectively. Twenty scans per second were recorded over the mass range 
85-500 m/z using the Advanced Scanning Speed Protocol (ASSP, Shimadzu Co.). 
 
Data processing was performed according to the methods described in previous reports 
[9,10]. Briefly, the MS data were exported in netCDF format. The peak detection and 
alignment were performed using the MetAlign software (Wageningen UR, The 
Netherlands). The resultant data were exported in CSV format and then analyzed with 
in-house analytical software (AIoutput). This software enables peak identification and 
semi-quantification using an in-house metabolite library. For semi-quantification, the 
peak height of each ion was calculated and normalized to the peak height of 
2-isopropylmalic acid as an internal standard. Names were assigned to each metabolite 
peak based on the method described in a previous report [10].
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Statistical analysis 
The patients (N=35) were allocated to the training or validation sets (Table 1). 
Regarding the healthy volunteers used for the training set, age- and sex-controlled 
samples were prepared (N=18). In the training set study, the OSCC patients’ 
preoperative serum metabolite levels were compared with those of the healthy 
volunteers using the Wilcoxon rank sum test, and comparisons between the OSCC 
patients’ pre- and postoperative serum metabolite levels were performed using the 
Wilcoxon signed-rank test. The metabolites that displayed significant differences 
(p<0.05) in their levels in both of these comparisons were selected for the validation set 
study. In the validation set study, the preoperative levels of the selected metabolites in 
the OSCC patients were compared with those of the healthy volunteers using the 
Wilcoxon rank sum test. Comparisons between the oral disease patients and OSCC 
patients, and between the pre- and postoperative serum metabolite levels of the oral 
disease patients were also performed. Based on these univariate analyses, tumor 
biomarker candidates were selected. In the training set, multiple logistic regression 
models were used to predict OSCC positivity and negativity. Receiver operating 
characteristic (ROC) analysis was carried out using JMP10 (SAS Institute Inc.), and the 
optimal cut-off, AUC, specificity, and sensitivity values were calculated. In the 
validation set and the training + validation set studies, the predictive models were 
evaluated using different samples, and the specificity and sensitivity of the models were 
examined using the cut-off values obtained from the training set. p values of less than 
0.05 were considered to indicate a significant difference. 
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Results 
In our GC/MS-based metabolomic analysis system, which mainly targeted 
water-soluble metabolites, 101 metabolites were detected in the subjects’ sera. Among 
the 101 metabolites, 1 metabolite; i.e., 2-isopropylmalic acid, was used as an internal 
standard. Therefore, this metabolite was excluded from the subsequent analyses, and a 
total of 100 metabolites were subjected to a comparative evaluation between OSCC 
patients and healthy volunteers.  
 
In the training set study, the preoperative serum metabolite levels of the OSCC patients 
were compared with those of the healthy volunteers using the Wilcoxon rank sum test. 
The training set was composed of OSCC patients (N=18) and age- and sex-matched 
healthy volunteers (N=18). Thirty-eight metabolites displayed significant differences 
between the pre-operative levels of the OSCC patients and those of the healthy 
volunteers (p<0.05) (Table 2). Then, a comparison of the OSCC patients’ pre- and 
postoperative metabolite levels was performed with the training set using the Wilcoxon 
signed-rank test, and 32 of the metabolites displayed significant alterations (Table 3). 
Thirteen metabolites; i.e., benzoic acid, glyceric acid, serine (3TMS), acetylsalicylic 
acid, lauric acid, N-acetyl-L-aspartic acid_1, asparagine, ornithine, glucuronate_1, 
heptadecanoate, phosphate, O-phosphoethanolamine and cysteine+cystine, were 
extracted from both of the abovementioned comparisons. The 13 selected metabolites 
were re-evaluated using the validation set, which was composed of OSCC patients 
(N=17) and healthy volunteers (N=17). As a result, 7 metabolites were selected as 
biomarker candidates (Table 4) because significant and similar alterations in their serum 
levels were observed in both the training and validation sets. Among the oral disease 
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patients, 6 of the metabolites (not including ornithine) displayed significantly different 
levels compared with healthy volunteers (Table 5). None of the 7 metabolites exhibited 
significant differences between their preoperative and postoperative levels in the oral 
disease patients (Table 6). In Figure 1, the differences in the levels of the 7 metabolites 
among tumor stages are shown. The 7 biomarker candidates displayed higher values in 
the OSCC patients than in the healthy volunteers at each stage, and the more advanced 
tumor stages tended to exhibit higher levels of each metabolite than the earlier tumor 
stages. ROC curves were prepared using the data for these 7 metabolites, and the cut-off, 
sensitivity, and specificity values of each metabolite were calculated (Table 7). In the 
training set, glyceric acid (77.7%), lauric acid (100%), N-acetyl-L-aspartic acid (94.4%), 
ornithine (88.8%), and heptadecanoate (83.3%) displayed relatively high sensitivity 
values (shown in brackets). Regarding specificity, lauric acid exhibited 100% specificity, 
and glyceric acid (77.7%), serine (3TMS) (94.4%), N-acetyl-L-aspartic acid (94.4%), 
asparagine (88.8%), and ornithine (94.4%) also demonstrated relatively high specificity 
values (shown in brackets). Lauric acid, N-acetyl-L-aspartic acid, and ornithine all 
displayed AUC values of greater than 80%. We then performed evaluations using 
multiple biomarkers to improve the reliability of our predictive models. Multiple 
logistic regression models involving pairs of the 7 selected metabolite biomarkers 
metabolites were employed as a new evaluation method (Table 8). As a result, we found 
that 4 pairs of biomarker candidates; i.e., ornithine+asparagine, ornithine+glyceric acid, 
ornithine+N-acetyl-L-aspartic acid, and ornithine+serine (3TMS), displayed sensitivity 
values of over 80% and specificity values of over 70% in the training set, validation set, 
and training+validation set. 
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Discussion 
The five-year survival rate of patients that are diagnosed with OSCC at an early stage is 
about 80-90%, but when it is diagnosed at an advanced stage the five-year survival rate 
is less than 30%, suggesting that it is important to detect OSCC at an early stage. The 
SCC antigen is used as a tumor marker of OSCC; however, it is estimated that it 
displays a sensitivity of about 30% during the early stages of the disease. Therefore, the 
SCC antigen is unsuitable for the early detection of OSCC, although it is partially useful 
for assessing the effects of treatment and the early detection of recurrence. In this study, 
it was suggested that serum metabolome analysis might be useful for diagnosing 
early-stage OSCC, and 7 metabolite biomarker candidates; i.e., glyceric acid, lauric acid, 
N-acetyl-L-aspartic acid, ornithine, heptadecanoate, serine, and asparagine, were found. 
In particular, a diagnostic system for OSCC based on combining several metabolite 
biomarker candidates exhibited high sensitivity and specificity. During the early stages 
of the disease; i.e., stages 1 and 2, the sensitivity values of the 7 metabolite biomarker 
candidates for OSCC were 77.7% for glyceric acid, 83.3% for lauric acid, 66.6% for 
N-acetyl-L-aspartic acid, 88.8% for ornithine, 66.6% for heptadecanoate, 38.8% for 
serine, and 50.0% for asparagine. In addition, their specificity values were 88.5% for 
glyceric acid, 100% for lauric acid, 97.1% for N-acetyl-L-aspartic acid, 85.7% for 
ornithine, 80.0% for heptadecanoate, 97.1% for serine, and 91.4% for asparagine. 
Furthermore, the sensitivity and specificity values of ornithine+asparagine, 
ornithine+glyceric acid, ornithine+N-acetyl-L-aspartic acid, and ornithine+serine were 
94.4% and 82.8%, 88.8% and 85.7%, 88.8% and 97.1%, and 88.8% and 82.8%, 
respectively. Thus, our results suggest that various biomarker pairs might be useful for 
the early detection of OSCC. 
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Many studies of OSCC biomarkers have been performed by various research groups, 
but most of them did not intend to find biomarkers for OSCC screening, e.g., they 
examined the utility of SCC antigen. The sensitivity of SCC antigen for early-stage 
OSCC is about 30%, although it was found to be useful for aiding the early diagnosis of 
recurrence [11]. In another paper, it was demonstrated that SCC antigen is a prognostic 
indicator of OSCC but is not useful for OSCC screening [12]. A previous study 
suggested that metabolomics analysis of plasma samples using nuclear magnetic 
resonance spectroscopy might be useful for OSCC screening [13], and the plasma levels 
of ornithine and asparagine were found to be higher in OSCC patients than in healthy 
volunteers [14], which was consistent with our findings. In addition, it was reported that 
most essential and non-essential amino acids displayed lower levels in OSCC patients 
than in healthy volunteers [15,16]; however, these results were partly caused by 
dysphagia and insufficient food intake. However, all of the patients in the study by 
Stefano Tiziani et al. [14] were provided with sufficient nutrition; therefore, the 
observed alterations in the levels of ornithine and asparagine might not have been due to 
the patients’ nutrition status. Among the 7 metabolite biomarker candidates extracted in 
the present study, lauric acid and heptadecanoate are lipid-soluble compounds that are 
found in food, suggesting that the effects of nutrition in OSCC and/or other oral 
diseases might partially contribute to these variations. In addition, the metabolite profile 
of the blood represents the sum of metabolic events in multiple organs, and it is difficult 
to understand the reasons for changing serum metabolite levels in OSCC patients from 
serum metabolite profiling. However, in this study we performed comparisons not only 
between OSCC patients and healthy volunteers but also between the pre- and 
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postoperative values of OSCC patients. In addition, the preoperative levels of patients 
with oral diseases other than OSCC were investigated to diminish the influence of oral 
surgery on our results and enhance the reliability of the OSCC biomarker candidates we 
selected. Therefore, our findings are considered to closely reflect the differences 
between the presence and absence of OSCC. In particular, the level of ornithine did not 
differ significantly between the healthy volunteers and oral disease patients (Table 5); 
therefore, this metabolite might be heavily involved in OSCC. Heavy smoking and 
alcohol consumption are primary causes of OSCC. Moreover, a correlation between 
human papillomavirus (HPV) positivity and OSCC has also been found recently. 
However, the relationships between these risk factors and the metabolome have not 
been elucidated. To establish a metabolomics-based method for detecting early-stage 
OSCC, it will be necessary to investigate whether these risk factors influence the serum 
metabolite profile. 
 
In conclusion, the present study could represent a first step towards a novel serum 
metabolomics-based screening method for OSCC. The extracted serum metabolites 
were demonstrated to be more effective at detecting OSCC than conventional tumor 
biomarkers; i.e., they displayed high sensitivity. Moreover, based on comparisons of the 
pre- and postoperative values of OSCC patients, this novel approach might also be 
useful for diagnosing recurrence. This study was limited to analyses of serum samples 
obtained from OSCC patients, and comparative evaluations between OSCC and other 
forms of cancer should be performed in future. Thus, it will be necessary to perform a 
further study involving many serum samples from individuals with a variety of 
conditions. Taken together, our findings highlight the importance of large-scale studies 
14 
 
aimed at developing metabolomics-based methods for detecting early-stage OSCC. 
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TABLE LEGENDS 
Table 1. Subject information for the training and validation sets 
The cancer patients in this study all had squamous cell carcinoma. There was no 
significant difference (p>0.05) in any of the background characteristics between the 
OSCC group and healthy volunteer group according to the Wilcoxon rank sum test.  
 
Table 2. A list of metabolites whose serum levels differed significantly (p<0.05) 
between the OSCC patients and healthy volunteers in the training set 
The values are shown as fold-induction values (the peak intensity of the OSCC patients 
(n=18) divided by that of the healthy volunteers (n=18)). P values were calculated using 
the Wilcoxon rank sum test. 
 
Table 3. A list of metabolites that displayed significantly different (p<0.05) pre- 
and postoperative serum levels in the OSCC patients 
P values were calculated using the Wilcoxon signed-rank test. 
 
Table 4. A list of metabolites (from among the 13 selected metabolites) whose 
serum levels differed significantly (p<0.05) between the OSCC patients and healthy 
volunteers in the validation set 
Values are represented as fold-induction values (the peak intensity of the OSCC patients 
(n=17) divided by that of the healthy volunteers (n=17)). P values were calculated using 
the Wilcoxon rank sum test. The 13 selected metabolites, whose serum levels differed 
significantly between the preoperative OSCC patients and the healthy volunteers as well 
as between the pre- and postoperative OSCC patients in the training set (p<0.05), were 
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evaluated, and then the listed metabolites were selected. 
 
Table 5. A list of metabolites whose serum levels displayed significant differences 
(p<0.05) between the oral disease patients and healthy volunteers 
Values are represented as fold-induction values (the peak intensity of the oral disease 
patients (n=12) divided by that of the healthy volunteers (n=35; data are from the 
training set + validation set)). P values were calculated using the Wilcoxon rank sum 
test. The oral disease patients had the following conditions: jaw deformities (n=9), a 
bone graft (n=1), a fractured jaw (n=1), or a benign tumor (n=1). The mean age of the 
oral disease patients was 28.9, and the male to female ratio was 5:7.  
 
Table 6. A list of metabolites whose pre- and postoperative serum levels in oral 
disease patients were significantly different (p<0.05) 
P values were calculated using the Wilcoxon rank sum test. The 12 preoperative samples 
were obtained from patients with the following oral conditions: jaw deformities (n=9), a 
bone graft (n=1), a fractured jaw (n=1), or a benign tumor (n=1). The 10 postoperative 
samples were collected from patients with the following conditions: jaw deformities 
(n=7), a bone graft (n=1), a fractured jaw (n=1), or a benign tumor (n=1). The mean age 
and male to female ratio of the oral disease patients were 28.9 and 5:7 for the 
preoperative samples and 29.7 and 1:1 for the postoperative samples, respectively. 
 
Table 7. Sensitivity, specificity, and AUC values of the 7 biomarker candidates 
Sensitivity, specificity, and AUC values were calculated in the training set, validation 
set, and training + validation set using ROC analysis. 
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Table 8. Sensitivity, specificity, and AUC values of metabolite pairs selected from 
among the 7 biomarker candidates 
The metabolite pairs were selected from among the 7 biomarker candidates and had 
their sensitivity, specificity, and AUC values evaluated by logistic regression analysis. 
 
 
FIGURE LEGENDS 
Figure 1. The serum levels of the 7 selected biomarker candidates according to 
clinical stage 
The 7 selected biomarker candidates included glyceric acid, serine, lauric acid, 
N-acetyl-L-aspartic acid, asparagine, ornithine, and heptadecanoate. The letter ‘a’ 
indicates a significant difference according to the Steel-Dwass test (p<0.05). The data 
were obtained from the training + validation set. 
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Table 1. Subject information for the training and validation sets 
   Training set   Validation set 
   OSCC patients Healthy volunteers   OSCC patients Healthy volunteers 
N   18 18  17 17 
 Male  13 13  11 12 
 Female  5 5  6 5 
        
Age  (years)       
 Mean  66.5 66.6  65.8 64.8 
 Range  38-88 59-75  23-87 57-75 
        
TNM stage I  4 -  4 - 
 II  6 -  4 - 
 III  2 -  4 - 
 IV  6 -  5 - 
        
Cancer location    Tongue   7 -  6 - 
 Gingiva  7 -  5 - 
 Cheek  2 -  4 - 
 Floor of the mouth  2 -  1 - 
  Lip  0 -  1 - 
The cancer patients in this study all had squamous cell carcinoma. There was no significant difference (p>0.05) in any of the background 
characteristics between the OSCC group and healthy volunteer group according to the Wilcoxon rank sum test.  
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Table 2. A list of metabolites whose serum levels differed significantly (p<0.05) between the OSCC patients and healthy volunteers in the training set 
Compound name Fold induction  p value 
 (cancer/healthy)  
Lactic acid 1.57  <0.0001 
Oxalate 1.91  0.0062 
Malonic acid 0.10  0.0003 
Urea 1.67  0.0007 
Benzoic acid 1.40  0.0155 
2-Aminoethanol 1.48  0.009 
Phosphate 0.81  0.0279 
Glycine (3TMS) 1.34  0.0009 
Succinic acid (or aldehyde) 1.24  0.009 
Glyceric acid 1.48  0.0025 
Serine (3TMS) 1.36  0.0382 
Thymine 0.24  0.0025 
Acetylsalicylic acid 2.69  0.0237 
Aspartic acid 1.66  0.0005 
Pyroglutamic acid 1.31  0.0068 
Glutamic acid 1.82  0.0005 
Phenylalanine 1.50  0.0008 
p-Hydroxybenzoic acid 10.25  <0.0001 
4-Hydroxyphenylacetic acid 2.59 0.0068 
Lauric acid 2.54  <0.0001 
N-acetyl-L-aspartic acid_1 2.35  <0.0001 
Ribose 0.49  <0.0001 
Asparagine 1.25  0.0119 
Xylitol 1.64  0.0013 
Arabitol 2.28  <0.0001 
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Orotic acid 3.57  <0.0001 
O-Phosphoethanolamine 0.77  0.0257 
Ornithine 1.58  <0.0001 
Glucose_1 1.31  0.0006 
Sebacic acid 0.58  0.0042 
Galactosamine_1  0.38  0.0002 
Glucuronate_1 0.995 0.0354 
Inositol 0.86  0.0042 
Heptadecanoate 1.38  0.0142 
Kynurenine 1.75  0.048 
Tryptophan 0.69  0.0038 
Spermidine 2.79 0.0445 
Cysteine+Cystine 0.80 0.0082 
The values are shown as fold-induction values (the peak intensity of the OSCC patients (n=18) divided by that of the healthy volunteers (n=18)). P 
values were calculated using the Wilcoxon rank sum test. 
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Table 3. A list of metabolites that displayed significantly different (p<0.05) pre- and postoperative serum levels in the OSCC patients  
Compound name p value 
Glycolic acid 0.0182 
Sarcosine 0.0023 
Ketoisoleucine_1 0.0182 
Valine (2TMS) 0.0208 
Benzoic acid 0.0432 
Phosphate 0.0208 
Isoleucine 0.0034 
Threonine (2TMS) 0.0047 
Glyceric acid 0.0237 
Serine (3TMS) 0.0483 
Nonanoic acid (C9) 0.0056 
Homoserine 0.0483 
Acetylsalicylic acid 0.0268 
Methionine 0.0023 
Pyrogallol 0.004 
Lauric acid <0.0001 
N-acetyl-L-aspartic acid_1 <0.0001 
Asparagine 0.001 
1,6-Anhydroglucose 0.0001 
Glutamine 0.0007 
4-Hydroxymandelate 0.0047 
O-Phosphoethanolamine 0.0432 
Theanine_2 0.0047 
Ornithine 0.0237 
Cadaverine 0.0268 
Tagatose_2 (or Psicose_2) 0.0432 
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-Sorbopyranose_1 (or Fructose_1) 0.0342 
Histidine 0.0034 
Glucuronate_1 0.0483 
1-Hexadecanol 0.0008 
Heptadecanoate <0.0001 
Cysteine+Cystine 0.0003 
P values were calculated using the Wilcoxon signed-rank test. 
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Table 4. A list of metabolites (from among the 13 selected metabolites) whose serum levels differed significantly (p<0.05) between the OSCC 
patients and healthy volunteers in the validation set 
Compound name Fold induction p value 
 (cancer/control)  
Glyceric acid 2.26  <0.0001 
Serine (3TMS) 2.68  <0.0001 
Lauric acid 3.71  <0.0001 
N-acetyl-L-aspartic acid_1 3.06  <0.0001 
Asparagine 2.55  <0.0001 
Ornithine 1.56  0.0003 
Heptadecanoate 2.30  <0.0001 
Values are represented as fold-induction values (the peak intensity of the OSCC patients (n=17) divided by that of the healthy volunteers (n=17)). P 
values were calculated using the Wilcoxon rank sum test. The 13 selected metabolites, whose serum levels differed significantly between the 
preoperative OSCC patients and the healthy volunteers as well as between the pre- and postoperative OSCC patients in the training set (p<0.05), 
were evaluated, and then the listed metabolites were selected. 
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Table 5. A list of metabolites whose serum levels displayed significant differences (p<0.05) between the oral disease patients and healthy volunteers  
Compound name Fold induction p value 
 (oral disease /healthy)  
Lactic acid 1.28  0.0108 
Glycolic acid 1.74  <0.0001 
Hydroxybutyrate 1.72  0.0009 
Oxalate 2.00  0.0013 
2-Aminobutyric acid 1.28  0.0441 
Ketoisoleucine_1 1.28  0.024 
Malonic acid 0.09  0.0308 
Valine (2TMS) 1.32  0.0348 
2-Aminoethanol 1.42  0.0163 
Phosphate 1.26  0.0101 
Threonine (2TMS) 1.42  0.0052 
Glycine (3TMS) 1.23  0.0036 
Succinic acid (or aldehyde) 1.62  0.0101 
Glyceric acid 2.44  <0.0001 
Uracil 0.94  0.0116 
Serine (3TMS) 1.74  0.0009 
Nonanoic acid (C9) 1.55  0.0022 
Thymine 0.19  0.0441 
Homoserine 1.39  0.037 
Malic acid 1.30  0.0308 
Homoserine lactone 1.17  0.0045 
Acetylsalicylic acid 2.44  <0.0001 
Aspartic acid 1.79  <0.0001 
Methionine 1.29  0.0495 
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trans-4-hydroxy-L-proline 1.47  0.0174 
Pyroglutamic acid 1.23  0.0124 
Glutamic acid 2.17  0.0001 
Phenylalanine 1.61  0.0006 
p-Hydroxybenzoic acid 15.70 <0.0001 
4-Hydroxyphenylacetic acid 1.22  0.0081 
Arabinose 0.74  0.0007 
Lauric acid 3.76  <0.0001 
N-acetyl-L-aspartic acid_1 2.94  <0.0001 
Ribulose 1.27  0.0045 
Ribose 0.44  <0.0001 
Asparagine 1.47  0.0036 
Xylitol 1.34  0.0163 
1,6-Anhydroglucose 2.21  0.0416 
Arabitol 1.60  0.037 
Theanine_2 0.48  0.0441 
Hypoxanthine 1.67  <0.0001 
Lysine (3TMS) 0.60  0.0328 
α-Sorbopyranose_1 (or Fructose_1) 2.19  0.0002 
Mannose_1 0.83  0.0308 
Sebacic acid 0.42  0.0005 
Gulcono-1,4-lactone 0.49  0.0041 
Galactosamine_1  0.30  0.0416 
Glucuronate_1 0.54  0.0001 
1-Hexadecanol 0.75  0.0108 
Inositol 0.85  0.0108 
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N--acetyl-L-lysine_2 3.59  0.0015 
Heptadecanoate 1.59  0.0017 
Kynurenine 1.46  0.0441 
Spermidine 2.17  0.003 
Cysteine+Cystine 0.73  0.0348 
Values are represented as fold-induction values (the peak intensity of the oral disease patients (n=12) divided by that of the healthy volunteers (n=35; 
data are from the training set + validation set)). P values were calculated using the Wilcoxon rank sum test. The oral disease patients had the 
following conditions: jaw deformities (n=9), a bone graft (n=1), a fractured jaw (n=1), or a benign tumor (n=1). The mean age of the oral disease 
patients was 28.9, and the male to female ratio was 5:7.  
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Table 6. A list of metabolites whose pre- and postoperative serum levels in oral disease patients were significantly different (p<0.05)  
Compound name p value 
Malonic acid 0.0272 
Nonanoic acid (C9) 0.0378 
Homoserine 0.0076 
4-Hydroxyphenylacetic acid 0.0027 
Arabitol 0.0161 
Ribitol 0.0001 
Glucarate 0.0378 
P values were calculated using the Wilcoxon rank sum test. The 12 preoperative samples were obtained from patients with the following oral 
conditions: jaw deformities (n=9), a bone graft (n=1), a fractured jaw (n=1), or a benign tumor (n=1). The 10 postoperative samples were collected 
from patients with the following conditions: jaw deformities (n=7), a bone graft (n=1), a fractured jaw (n=1), or a benign tumor (n=1). The mean age 
and male to female ratio of the oral disease patients were 28.9 and 5:7 for the preoperative samples and 29.7 and 1:1 for the postoperative samples, 
respectively. 
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Table 7. Sensitivity, specificity, and AUC values of the 7 biomarker candidates 
 Training set   Validation set  Training + validation set 
Compounds Sensitivity Specificity AUC   Sensitivity Specificity AUC   Sensitivity Specificity AUC  
Glyceric acid 77.7  77.7  0.79630   76.4  94.1  0.97232   77.1  88.5  0.88082  
Serine (3TMS) 55.5  94.4  0.70370       35.2  100  0.95848   42.8  97.1  0.79755  
Lauric acid 100  100  1.00000   70.5  100  0.99308   82.8  100  0.97796  
N-acetyl-L-aspartic acid_1 94.4  94.4  0.94136   52.9  100  0.96540   71.4  97.1  0.91755  
Asparagine 61.1  88.8  0.74691   52.9  94.1  0.95502   54.2  91.4  0.83592  
Ornithine 88.8  94.4  0.94753   88.2  70.5  0.86851   88.5  85.7  0.90204  
Heptadecanoate 83.3  61.1  0.74074   58.8  94.1  0.94810   71.4  80.0  0.81061  
Sensitivity, specificity, and AUC values were calculated in the training set, validation set, and training + validation set using ROC analysis. 
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Table 8. Sensitivity, specificity, and AUC values of metabolite pairs selected from among the 7 biomarker candidates  
 Training set   Validation set  Training+validation set 
Compounds Sensitivity Specificity AUC   Sensitivity Specificity AUC   Sensitivity Specificity AUC  
Asparagine+Heptadecanoate 72.2 94.4 0.87037  41.1 100 0.9654  57.1 97.1 0.86776 
Asparagine+Lauric acid 100 100 1  58.8 100 0.91176  80.0 100 0.9551 
Asparagine+N-acetyl-L-aspartic acid_1 94.4 94.4 0.93827  82.3 100 0.98962  74.2 97.1 0.92653 
Asparagine+Ornithine 94.4 88.8 0.94444  94.1 76.4 0.91003  94.2 82.8 0.92408 
Asparagine+Serine (3TMS) 61.1 94.4 0.76235  35.2 94.1 0.95502  48.5 94.2 0.84163 
Asparagine+Glyceric acid 77.7 83.3 0.85494  70.5 94.1 0.96886  74.2 88.5 0.89469 
Glyceric acid+Heptadecanoate 94.4 83.3 0.93827  64.7 100 0.97924  80 91.4 0.91673 
Glyceric acid+Lauric acid 100 100 1  64.7 100 0.94118  82.8 100 0.95102 
Glyceric acid+N-acetyl-L-aspartic acid_1 94.4 94.4 0.95062  58.8 100 1  74.2 97.1 0.94041 
Glyceric acid+Serine (3TMS) 72.2 94.4 0.83333  64.7 100 0.97578  68.5 97.1 0.88898 
Lauric acid+Heptadecanoate 100 100 1  70.5 100 0.91176  85.7 100 0.95224 
Lauric acid+N-acetyl-L-aspartic acid_1 100 100 1  64.7 100 0.91176  82.8 100 0.95347 
N-acetyl-L-aspartic acid_1+Heptadecanoate 94.4 94.4 0.93827  52.9 100 0.95502  74.2 97.1 0.91429 
Ornithine+Glyceric acid 88.8 94.4 0.94444  88.2 76.4 0.89273  88.5 85.7 0.91429 
Ornithine+Heptadecanoate 88.8 100 0.97222  64.7 94.1 0.9308  77.1 97.1 0.94694 
Ornithine+Lauric acid 100 100 1  58.8 100 0.85294  80.0 100 0.92653 
Ornithine+N-acetyl-L-aspartic acid_1 94.4 100 0.95988  88.2 94.1 0.97232  91.4 97.1 0.97061 
Ornithine+Serine (3TMS) 94.4 88.8 0.93519  88.2 76.4 0.88235  91.4 82.8 0.90612 
Serine (3TMS)+Heptadecanoate 77.7 72.2 0.81481  41.1 100 0.97232  60 85.7 0.84327 
Serine (3TMS)+Lauric acid 100 100 1  58.8 100 0.96886  80.0 100 0.97306 
Serine (3TMS)+N-acetyl-L-aspartic acid_1 94.4 94.4 0.94136  52.9 100 0.96194  74.2 97.1 0.91837 
The metabolite pairs were selected from among the 7 biomarker candidates and had their sensitivity, specificity, and AUC values evaluated by 
logistic regression analysis. 
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